Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer

Surgical resection is a standard therapeutic approach for some cases of non-small cell lung cancer (NSCLC). Fluorodeoxyglucose positron-emission tomography (FDG-PET) is now widely used in clinical diagnosis and staging of various types of cancers, including NSCLC. We investigated whether the maximum...

Full description

Saved in:
Bibliographic Details
Published inAnticancer research Vol. 34; no. 2; pp. 805 - 810
Main Authors Muto, Jun, Hida, Yasuhiro, Kaga, Kichizo, Ohtaka, Kazuto, Okamoto, Shozo, Tamaki, Nagara, Nakada-Kubota, Reiko, Hirano, Satoshi, Matsui, Yoshiro
Format Journal Article
LanguageEnglish
Published Greece 01.02.2014
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Surgical resection is a standard therapeutic approach for some cases of non-small cell lung cancer (NSCLC). Fluorodeoxyglucose positron-emission tomography (FDG-PET) is now widely used in clinical diagnosis and staging of various types of cancers, including NSCLC. We investigated whether the maximum standardized uptake value (SUVmax) of primary tumors is useful in predicting the extent of lymph node involvement. We retrospectively evaluated 354 patients with NSCLC who underwent surgery following FDG-PET and computed tomographic (CT) scans in our hospital. Logistic regression analyses were used to assess associations between categories (age, sex, tumor size, SUVmax, serum Squamous cell carcinoma-related antigen (SCC), cytokeratin 19 fragment (CYFRA), carcinoembryonic antigen (CEA), Brinkman index and histologic type. Differences in SUVmax of primary tumors between positive and negative lymph node involvement were examined by Mann-Whitney U-test. SUVmax of primary tumors in patients without lymph node involvement was significantly lower than in those with involvement, in both adenocarcinoma and squamous cell carcinomas (median, 2.2 vs. 4.9 in adenocarcinoma and 5.0 vs. 8.1 in squamous cell carcinoma, p<0.001 for both). Among node-positive cases, the lowest primary tumor SUVmax was 1.24 in an adenocarcinoma and 2.05 in a squamous cell carcinoma. However, primary tumor SUVmax and extent of lymph node metastases showed no significant differences between pN1 and pN2, single and multiple lymph node involvement, or single and multiple station involvement. A low primary tumor SUVmax in NSCLC may help identify patients with no lymph node involvement. However, SUVmax does not discriminate between minimal and extended lymph node involvement.
AbstractList Surgical resection is a standard therapeutic approach for some cases of non-small cell lung cancer (NSCLC). Fluorodeoxyglucose positron-emission tomography (FDG-PET) is now widely used in clinical diagnosis and staging of various types of cancers, including NSCLC. We investigated whether the maximum standardized uptake value (SUVmax) of primary tumors is useful in predicting the extent of lymph node involvement. We retrospectively evaluated 354 patients with NSCLC who underwent surgery following FDG-PET and computed tomographic (CT) scans in our hospital. Logistic regression analyses were used to assess associations between categories (age, sex, tumor size, SUVmax, serum Squamous cell carcinoma-related antigen (SCC), cytokeratin 19 fragment (CYFRA), carcinoembryonic antigen (CEA), Brinkman index and histologic type. Differences in SUVmax of primary tumors between positive and negative lymph node involvement were examined by Mann-Whitney U-test. SUVmax of primary tumors in patients without lymph node involvement was significantly lower than in those with involvement, in both adenocarcinoma and squamous cell carcinomas (median, 2.2 vs. 4.9 in adenocarcinoma and 5.0 vs. 8.1 in squamous cell carcinoma, p<0.001 for both). Among node-positive cases, the lowest primary tumor SUVmax was 1.24 in an adenocarcinoma and 2.05 in a squamous cell carcinoma. However, primary tumor SUVmax and extent of lymph node metastases showed no significant differences between pN1 and pN2, single and multiple lymph node involvement, or single and multiple station involvement. A low primary tumor SUVmax in NSCLC may help identify patients with no lymph node involvement. However, SUVmax does not discriminate between minimal and extended lymph node involvement.
AIMSurgical resection is a standard therapeutic approach for some cases of non-small cell lung cancer (NSCLC). Fluorodeoxyglucose positron-emission tomography (FDG-PET) is now widely used in clinical diagnosis and staging of various types of cancers, including NSCLC. We investigated whether the maximum standardized uptake value (SUVmax) of primary tumors is useful in predicting the extent of lymph node involvement.PATIENTS AND METHODSWe retrospectively evaluated 354 patients with NSCLC who underwent surgery following FDG-PET and computed tomographic (CT) scans in our hospital. Logistic regression analyses were used to assess associations between categories (age, sex, tumor size, SUVmax, serum Squamous cell carcinoma-related antigen (SCC), cytokeratin 19 fragment (CYFRA), carcinoembryonic antigen (CEA), Brinkman index and histologic type. Differences in SUVmax of primary tumors between positive and negative lymph node involvement were examined by Mann-Whitney U-test.RESULTSSUVmax of primary tumors in patients without lymph node involvement was significantly lower than in those with involvement, in both adenocarcinoma and squamous cell carcinomas (median, 2.2 vs. 4.9 in adenocarcinoma and 5.0 vs. 8.1 in squamous cell carcinoma, p<0.001 for both). Among node-positive cases, the lowest primary tumor SUVmax was 1.24 in an adenocarcinoma and 2.05 in a squamous cell carcinoma. However, primary tumor SUVmax and extent of lymph node metastases showed no significant differences between pN1 and pN2, single and multiple lymph node involvement, or single and multiple station involvement.CONCLUSIONA low primary tumor SUVmax in NSCLC may help identify patients with no lymph node involvement. However, SUVmax does not discriminate between minimal and extended lymph node involvement.
Author Kaga, Kichizo
Nakada-Kubota, Reiko
Hida, Yasuhiro
Ohtaka, Kazuto
Okamoto, Shozo
Tamaki, Nagara
Muto, Jun
Hirano, Satoshi
Matsui, Yoshiro
Author_xml – sequence: 1
  givenname: Jun
  surname: Muto
  fullname: Muto, Jun
  email: yhida@med.hokudai.ac.jp
  organization: Department of Cardiovascular and Thoracic Surgery, Hokkaido University Graduate School of Medicine, North 15, West 7, Kita-ku, Sapporo 060-8638, Japan. yhida@med.hokudai.ac.jp
– sequence: 2
  givenname: Yasuhiro
  surname: Hida
  fullname: Hida, Yasuhiro
– sequence: 3
  givenname: Kichizo
  surname: Kaga
  fullname: Kaga, Kichizo
– sequence: 4
  givenname: Kazuto
  surname: Ohtaka
  fullname: Ohtaka, Kazuto
– sequence: 5
  givenname: Shozo
  surname: Okamoto
  fullname: Okamoto, Shozo
– sequence: 6
  givenname: Nagara
  surname: Tamaki
  fullname: Tamaki, Nagara
– sequence: 7
  givenname: Reiko
  surname: Nakada-Kubota
  fullname: Nakada-Kubota, Reiko
– sequence: 8
  givenname: Satoshi
  surname: Hirano
  fullname: Hirano, Satoshi
– sequence: 9
  givenname: Yoshiro
  surname: Matsui
  fullname: Matsui, Yoshiro
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24511016$$D View this record in MEDLINE/PubMed
BookMark eNo1kMtOwzAQRS0EorTwC8hLNpFsJ3GaJap4SZXY0HXkxJPW4EeI7dLwXXwgBspiHtKcezUzc3RqnYUTdEGrmmZVmZMZmnv_Sgjn9TI_RzNWlJQSyi_Q18YDdj024qBMNNgHYaUYpfoEieMQxBvgvdAxQRb3OrrRSXCHaatj55J0cF6F0dkMjPJeJSg447ajGHYTVhYPI0jVBWW3WE9m2GGb9Gmwd3oPBmz4hURQqfX4Q4VdkigjximRNvNGaI07SEnH5NEJ28F4ic56oT1cHesCbe7vXlaP2fr54Wl1u84GRmnIhGgLTklb5iWtebdkFfSUsbaSkvOSFILKnjBGoV32In2Jy2UuU7C8rqsqNQt08-c7jO49gg9NOvJnGWHBRd_Qoq4p44SwhF4f0dgakM3xiOb_0_k3iy2AjA
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1791-7530
EndPage 810
ExternalDocumentID 24511016
Genre Journal Article
GroupedDBID ---
.55
.GJ
23M
53G
5GY
5RE
5VS
ADBBV
AENEX
AFFNX
AIZAD
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BTFSW
CGR
CUY
CVF
DIK
EBS
ECM
EIF
EJD
F5P
H13
KQ8
L7B
NPM
OK1
P2P
RHF
RHI
SJN
UDS
VRB
W8F
X7M
ZGI
ZXP
7X8
ID FETCH-LOGICAL-p211t-aab4610b535196c827ef122b7dd66504a1df0221eb8fa5306d83dd83239977d83
IngestDate Thu Oct 24 23:47:00 EDT 2024
Sat Sep 28 07:58:27 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords FDG-PET
non-small cell lung cancer
SUVmax
lymph node involvement
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p211t-aab4610b535196c827ef122b7dd66504a1df0221eb8fa5306d83dd83239977d83
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 24511016
PQID 1499126002
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_1499126002
pubmed_primary_24511016
PublicationCentury 2000
PublicationDate 2014-Feb
20140201
PublicationDateYYYYMMDD 2014-02-01
PublicationDate_xml – month: 02
  year: 2014
  text: 2014-Feb
PublicationDecade 2010
PublicationPlace Greece
PublicationPlace_xml – name: Greece
PublicationTitle Anticancer research
PublicationTitleAlternate Anticancer Res
PublicationYear 2014
SSID ssj0066983
Score 2.1599076
Snippet Surgical resection is a standard therapeutic approach for some cases of non-small cell lung cancer (NSCLC). Fluorodeoxyglucose positron-emission tomography...
AIMSurgical resection is a standard therapeutic approach for some cases of non-small cell lung cancer (NSCLC). Fluorodeoxyglucose positron-emission tomography...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 805
SubjectTerms Adult
Aged
Aged, 80 and over
Carcinoma, Non-Small-Cell Lung - diagnostic imaging
Carcinoma, Non-Small-Cell Lung - metabolism
Carcinoma, Non-Small-Cell Lung - pathology
Female
Fluorodeoxyglucose F18 - pharmacokinetics
Humans
Lung Neoplasms - diagnostic imaging
Lung Neoplasms - metabolism
Lung Neoplasms - pathology
Lymph Nodes - diagnostic imaging
Lymph Nodes - metabolism
Lymph Nodes - pathology
Lymphatic Metastasis
Male
Middle Aged
Positron-Emission Tomography
Radiopharmaceuticals - pharmacokinetics
Retrospective Studies
Title Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer
URI https://www.ncbi.nlm.nih.gov/pubmed/24511016
https://search.proquest.com/docview/1499126002
Volume 34
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3db5swEMCttA_TXqZ9r-s23aS9RUzFgIHHamuVrR97SaTsCRkwCmqAiICU5u_qH7g74xCmblK3hyDkgBO4n-y7892ZsU-Ow3FkDH1LqsS13ExKK-Y8sPzYS3xPZKjPkb_j6lpMZu73uTcfjTaDqKW2iT8n2z_mlfyPVLEN5UpZsv8g2b5TbMBzlC8eUcJ4fJCMZ50jvpCbvGiL3i2Qb1GLbFeNvFFjKuataEUgW7YVDpaq2tzuwtR1wFZdlRbt-UZeM1REC1PCWkeX17SKo-Oil7co9XGJ9-MXOKLpKuN6dwFTmNVkya1M8YoSe10XtOxNKwPjZUupvQRYPdSGT0vypFPr2BQdWuwBaLo1oband5KnWtP9KdftIq-rfq6QnXP4ItcBhL3beIEvwCS8bbG3oX_Ddnch0TQ9dWOyH9oWWlUnw0HbeEDzge3cjcDBiTeczE3M7G91tq9_ROezy8toejafHrADx6ZQ0K_fLnYzuBAhVZH8m8WhNY_pU_bEmAxw2sn_GRup8jl7dGWCIl6wO8QAqgwMBjDEADoMQGMAVQn3MYB7GMAeA8hL2GMAGgMgDGCAgb7IYACEARgMoMcACAMgDKAT-Es2Oz-bfplYZjMOa8Vtu7GkjKk0f-zRjo4iCbivMpvz2E9TgVq-K-00Q33QVnGQSRSWSAMnxQ_lTvs-nrxih_ij6g2DEK8QmVApDxI3CVUYpI7rKD9RsYwdJY7Yx92rj_DB6Q_KUlXtGu1UNGdoSwV-xF53MonME0WcKu2hAfP2AXcfs8d71N6xw6Zu1XtULpv4gybhF718kRk
link.rule.ids 315,783,787
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Use+of+maximum+standardized+uptake+value+on+fluorodeoxyglucose+positron-emission+tomography+in+predicting+lymph+node+involvement+in+patients+with+primary+non-small+cell+lung+cancer&rft.jtitle=Anticancer+research&rft.au=Muto%2C+Jun&rft.au=Hida%2C+Yasuhiro&rft.au=Kaga%2C+Kichizo&rft.au=Ohtaka%2C+Kazuto&rft.date=2014-02-01&rft.eissn=1791-7530&rft.volume=34&rft.issue=2&rft.spage=805&rft.epage=810&rft.externalDBID=NO_FULL_TEXT